Trial subject in the first case of Phase II clinical trial EDP167 dosing completed

EDP167 phase II clinical trial has successfully completed the first dose of the subject. The phase II clinical trial of EDP167 is a multicenter, dose exploration, open-label trial targeting homozygous familial hypercholesterolemia (HoFH) adult patients. The trial aims to evaluate the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in low-density lipoprotein cholesterol (LDL-C) levels compared to baseline after 24 weeks of initial dose. The evaluation of the primary endpoint is expected to be completed in the fourth quarter of 2026.